[1] CHEN YD, CHEN JY, FU GS, et al.Chinese expert consensus on adverse drug reactions related to iodine contrast agent angiography[J]. Chinese Journal of Interventional Cardiology(中国介入心脏病学杂志), 2014, 22(6): 341-348. [2] Contrast Agents Safe Use Working Group of Chinese Society of Radiology Chinese Medical Association. Guidelines for the use of iodine contrast agents (2nd Edition)[J]. National Medical Journal of China(中华医学杂志), 2014, 94(43): 3363-3369. [3] Kidney Disease: improving global outcomes (KDIGO). KDIGO Clinical practice guideline for acute kidney injury[J]. Journal of The International Society of Nephrology, 2012(Suppl 2): 1-138. [4] CHRISTIANSEN C, PICHLER WJ, SKOTLAND T.Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations[J]. EurRadiol, 2000, 10(12): 1965-1975. [5] LOH S, BAGHERI S, KATZBERG RW, et al.Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement[J]. Radiology, 2010, 255(3): 764-771. [6] MING Q, SU Y, LIU WJ, et al.Analysis of contrast media iodixanol-induced delayed adverse reaction with the risk factors in general clinical practice[J]. Chinese Circulation Journal(中国循环杂志), 2014, 29(11): 903-906. [7] XU ZX.Comparative analysis of adverse drug reactions caused by iodixanol and iohexol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(2): 125-128. [8] WANG QS, LIANG CH.Adverse reactions of iodinated contrast agents and the strategies for their treatment[J]. Shanghai Medical & Pharmaceutical Journal(上海医药),2014, 35(13): 8-15. [9] SOLOMON RJ, NATARAJAN MK, DOUCET S, et al.Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease[J]. Circulation, 2007, 115(25): 3189-3196. [10] WANG SQ, WANG AD.Effects of Ioversol, iodixanol, iopromide on renal function in patients with early diabetic nephropathy[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 199-202. [11] LI JX, REN XJ, LI XQ.Influence of iodine contrast agent viscosity on microcirculation[J]. Chinese Journal of Radiology(中华放射学杂志), 2012, 46(7): 669-670. [12] ELLIS JH, COHAN RH.Reducing the risk of contrast-induced nephropathy: a perspective on the controversies[J]. AJR Am J Roentgenol, 2009, 192(6): 1544-1549. [13] CHEN S, CHEN YD, QIAN G, et al.Diagnosis and prevention strategy of contrast induced nephropathy[J]. Chinese Journal of Evidence-Bases Cardiovascular Medicine(中国循证心血管医学杂志), 2016, 8(5): 630-632. [14] HUANG J, YUAN MJ, MA SX, et al.Protective effects of salvianolate on contrast-induced nephropathy after primary percutaneous coronary intervention[J]. Chinese Journal of Interventional Cardiology(中国介入心脏病学杂志), 2017, 25(1): 35-41. [15] ZHANG P, LI XY, YANG SC, et al.Research progress of statins in the prevention of contrast induced acute kidney injury[J]. Modern Medicine Journal of China(中国现代医药杂志), 2017, 19(2): 101-104. [16] HUANG M, XU X, DU LG, et al.A meta-analysis of the effect of N-acetylcysteine on the prevention of contrast induced nephropathy after percutaneous coronary intervention[J]. Shandong Medical Journal(山东医药), 2016, 56(12): 54-56. [17] LI WJ, ZHAO ZJ, SUN DD.Percutaneous coronary intervention without contrast: case report[J]. Chinese Heart Journal(心脏杂志), 2016, 28(6): 747-749. |